Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Unlabeled Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Caution and personalized dose adjustment in patients with the following genotypes
  • Other genes that may be involved
  • Drug Interactions
  • Nutrition/Nutraceutical Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Austria: Reopro; Belgium: Reopro; Bulgaria: Reopro; Czech Republic: Reopro; Denmark: Reopro; Finland: Reopro; France: Reopro; Germany: Reopro; Greece: Reopro; Hungary: Reopro; Ireland: Reopro; Italy: Reopro; Luxembourg: Reopro; Netherlands: ReoPro; Poland: ReoPro; Portugal: ReoPro; Romania: ReoPro; Slovenia: Reopro; Spain: Reopro; Sweden: Reopro; UK: Reopro.

North America

Canada: Reopro; USA: Reopro.

Latin America

Brazil: Reopro; Mexico: Reopro.

Drug combinations


Abciximab: Mw: approx. 47600.01. (1) Immunoglobulin G~1~, (human-mouse monoclonal c7E3 clone p7E3VHhCg1 Fab fragment anti-human glycoprotein IIb/IIIa receptor), disulfide with human-mouse monoclonal c7E3 clone p7E3VkhCk light chain; (2) Immunoglobulin G~1~ (human-mouse monoclonal c7E3 clone p7E3VHhCg1 Fab fragment anti-human glycoprotein IIb/IIIa receptor), disulfide with human-mouse monoclonal c7E3 clone p7E3VkhCk light chain. CAS-143653-53-6 (1994).

Pharmacologic Category

Antithrombotic Agents; Platelet-aggregation Inhibitors; Glycoprotein IIb/IIIa Inhibitor. (ATC-Code: B01AC13).

Mechanism of action

Fab antibody fragment of the chimeric human-murine monoclonal antibody 7E3. Inhibits platelet aggregation by binding to IIb/IIIa receptors.

Therapeutic use

Prevention of acute cardiac ischemic complications in patients at high risk for abrupt closure of the treated coronary vessel and patients at risk of restenosis. Adjunct with heparin to prevent cardiac ischemic complications in patients with unstable angina not responding to conventional therapy when a percutaneous coronary intervention is scheduled within 24 hours.

Pregnancy and lactiation implications

Not known whether fetal harm can be caused or if reproduction capacity can be affected. Caution during lactation.

Unlabeled use

Myocardial infarction. Acute ischemic stroke.


Hypersensitivity. Active internal hemorrhage or recent GI or GU bleeding. History of cerebrovascular accident. Clotting abnormalities or recent administration of oral anticoagulants (within 7 days). Thrombocytopenia. Recent major surgery or trauma. Intracranial tumor. Arteriovenous malformation. Aneurysm. Severe uncontrolled hypertension. Vasculitis. Use of dextran before percutaneous transluminal coronary angioplasty. Concomitant use of another parentheral GP IIb/IIIa inhibitor.

Warnings and precautions

Anaphylaxis/hypersensitivity reactions, thrombocytopenia as well as diminished efficacy might occur due to human antichimeric antibody formation. Bleeding complications (use with extreme caution in platelet counts <150,000/mm^3^, hemorrhagic retinopathy, previous history of gastrointestinal disease, recent thrombolytic therapy and in chronic dialysis. Use caution with administration of other drugs affecting hemostasis. Diminished drug efficacy (human antichimeric antibody formation). Use with caution in patients weighing <75 kg or >65 years of age (increased risk of bleeding).



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart